TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) research

TEVA PHARMACEUTICAL INDUSTRIES LTD
ShareXLinkedInReddit
Sector
Pharmaceuticals
Last price
$40.22
As of

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-16.

As of . Source: SEC EDGAR filings for TEVA. Method and limitations.

SHARE THIS CARD

Share the TEVA intelligence card

A branded snapshot of TEVA: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion TEVA intelligence card preview
Post to X
LIVE TERMINAL

See TEVA live in the terminal

Track TEVA's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live TEVA terminal, free

Active signals for TEVA

FREE, NO ACCOUNT

Every signal on TEVA, as it fires

You are seeing 5 of 35 signals recorded on TEVA since 2026-05-30.

The five above all landed on 2026-09-06. The other 30 were recorded on 3 other days. 31 of the 35 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in TEVA (2026Q2)

Manager / securityMarket value% portfolioQoQ
MILLENNIUM MANAGEMENT LLCCUSIP 881624209 · 2026Q2$110.6M0.04%,
Bridgewater Associates, LPCUSIP 881624209 · 2026Q2$44.9M0.18%,
Point72 Asset Management, L.P.CUSIP 881624209 · 2026Q2$35.9M0.04%,
TWO SIGMA INVESTMENTS, LPCUSIP 881624209 · 2026Q2$7.8M0.01%,
D. E. Shaw & Co., Inc.CUSIP 881624209 · 2026Q2$6.1M0.00%,
CITADEL ADVISORS LLCCUSIP 881624209 · 2026Q2$2.5M0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, TEVA

TEVA against its peers

TEVA's operating margin of 12.5% ranks in the 56th percentile of 16 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-28 and 2025-12-31.

MetricTEVAPeer medianPercentilen
Revenue FY17.3B USD4.3B USD7021
Gross margin51.8%72.4%259
Operating margin12.5%-1.4%5616
Net margin8.2%7.7%5022
Return on equity17.8%9.0%5623
P / E33.2x19.7x7710

Peers (25): ZTS, GSK, VTRS, BMY, JAZZ, PFE, CORT, NVO, AXSM, AZN, NVS, AMRX, LQDA, MRK, TARS, AMLX, OGN, JNJ, GPCR, HRMY, SUPN, NKTR, OCUL, BHC, TRVI. Fiscal periods ending between 2025-12-28 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (TEVA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more TEVA signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TEVAand get the insider, 13F, options, and confluence read in one view.

Open the live TEVA terminal, free